Aldeyra 治療公司
US ˙ NasdaqCM ˙ US01438T1060

SecurityALDX / Aldeyra Therapeutics, Inc.
InstitutionBlackRock, Inc.
Latest Disclosed Ownership3,430,774 shares
Ownership 5.80%
BlackRock, Inc. ownership in ALDX / Aldeyra Therapeutics, Inc.

2024-01-29 - BlackRock, Inc. has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,430,774 shares of Aldeyra Therapeutics, Inc. (US:ALDX). This represents 5.8 percent ownership of the company. In their previous filing dated 2022-07-08 , BlackRock, Inc. had reported owning 974,947 shares, indicating an increase of 251.89 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2024-01-29 2024-01-29 13G 974,947 3,430,774 251.89 5.80 241.18
2022-07-08 2022-07-08 13G 3,228,811 974,947 -69.80 1.70 -69.64
2022-02-04 2022-02-04 13G 483,573 3,228,811 567.70 5.60 250.00
2020-07-10 2020-07-10 13G/A 1,584,625 483,573 -69.48 1.60 -71.93
2020-02-07 2020-02-07 13G 1,584,625 5.70

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F ALDEYRA THERAPEUTICS COM 01438T106 3,763,887 -86,216 -2.24 6,361 -68.11 0.0000
2026-02-12 2025-12-31 13F ALDEYRA THERAPEUTICS COM 01438T106 3,850,103 45,183 1.19 19,944 0.41 0.0003
2025-11-12 2025-09-30 13F ALDEYRA THERAPEUTICS COM 01438T106 3,804,920 -47,181 -1.22 19,862 34.62 0.0003
2025-08-12 2025-06-30 13F ALDEYRA THERAPEUTICS COM 01438T106 3,852,101 116,063 3.11 14,754 -31.32 0.0003
2025-05-02 2025-03-31 13F ALDEYRA THERAPEUTICS COM 01438T106 3,736,038 -54,152 -1.43 21,482 13.58 0.0005
2025-02-07 2024-12-31 13F ALDEYRA THERAPEUTICS COM 01438T106 3,790,190 55,782 1.49 18,913 -6.04 0.0004
2024-11-13 2024-09-30 13F ALDEYRA THERAPEUTICS COM 01438T106 3,734,408 112,459 3.10 20,128 67.90 0.0004
2024-08-13 2024-06-30 13F ALDEYRA THERAPEUTICS COM 01438T106 3,621,949 311,162 9.40 11,989 10.73 0.0003
2024-05-10 2024-03-31 13F ALDEYRA THERAPEUTICS COM 01438T106 3,310,787 -119,987 -3.50 10,826 -10.10 0.0003
2024-02-13 2023-12-31 13F ALDEYRA THERAPEUTICS COM 01438T106 3,430,774 59,642 1.77 12,042 -46.53 0.0003
2023-11-13 2023-09-30 13F ALDEYRA THERAPEUTICS COM 01438T106 3,371,132 140,718 4.36 22,519 -16.91 0.0006
2023-08-11 2023-06-30 13F ALDEYRA THERAPEUTICS COM 01438T106 3,230,414 2,245,432 227.97 27,103 177.13 0.0007
2023-05-12 2023-03-31 13F ALDEYRA THERAPEUTICS COM 01438T106 984,982 12,546 1.29 9,781 44.50 0.0003
2023-02-13 2022-12-31 13F ALDEYRA THERAPEUTICS COM 01438T106 972,436 2,350 0.24 6,768 30.66 0.0002
2022-11-14 2022-09-30 13F ALDEYRA THERAPEUTICS COM 01438T106 970,086 -4,861 -0.50 5,180 33.13 0.0002
2022-08-12 2022-06-30 13F ALDEYRA THERAPEUTICS COM 01438T106 974,947 -2,245,564 -69.73 3,891 -72.82 0.0001
2022-05-12 2022-03-31 13F ALDEYRA THERAPEUTICS COM 01438T106 3,220,511 -8,300 -0.26 14,315 10.84 0.0004
2022-02-10 2021-12-31 13F ALDEYRA THERAPEUTICS COM 01438T106 3,228,811 -35,131 -1.08 12,915 -54.93 0.0003
2021-11-09 2021-09-30 13F ALDEYRA THERAPEUTICS COM 01438T106 3,263,942 -11,842 -0.36 28,658 -22.79 0.0008
2021-08-11 2021-06-30 13F ALDEYRA THERAPEUTICS COM 01438T106 3,275,784 2,222,456 210.99 37,115 196.59 0.0010
2021-05-07 2021-03-31 13F ALDEYRA THERAPEUTICS COM 01438T106 1,053,328 273,024 34.99 12,514 133.82 0.0004
2021-02-05 2020-12-31 13F ALDEYRA THERAPEUTICS COM 01438T106 780,304 29,160 3.88 5,352 -3.83 0.0002
2020-11-06 2020-09-30 13F ALDEYRA THERAPEUTICS COM 01438T106 751,144 267,571 55.33 5,565 176.04 0.0002
2020-08-14 2020-06-30 13F ALDEYRA THERAPEUTICS COM 01438T106 483,573 -1,130,619 -70.04 2,016 -49.45 0.0001
2020-05-01 2020-03-31 13F ALDEYRA THERAPEUTICS COM 01438T106 1,614,192 29,567 1.87 3,988 -56.69 0.0002
2020-02-13 2019-12-31 13F ALDEYRA THERAPEUTICS COM 01438T106 1,584,625 -1,478 -0.09 9,207 10.17 0.0004
2019-11-08 2019-09-30 13F ALDEYRA THERAPEUTICS COM 01438T106 1,586,103 47,637 3.10 8,357 -9.47 0.0004
2019-08-22 2019-06-30 13F/A-1 ALDEYRA THERAPEUTICS COM 01438T106 1,538,466 196,463 14.64 9,231 -23.82 0.0004
2019-08-13 2019-06-30 13F ALDEYRA THERAPEUTICS COM 01438T106 1,538,466 196,463 9,231
2019-05-09 2019-03-31 13F ALDEYRA THERAPEUTICS COM 01438T106 1,342,003 43,288 3.33 12,117 12.41 0.0005
2019-02-08 2018-12-31 13F ALDEYRA THERAPEUTICS COM 01438T106 1,298,715 501,927 62.99 10,779 -1.97 0.0005
2018-11-09 2018-09-30 13F ALDEYRA THERAPEUTICS COM 01438T106 796,788 16,044 2.05 10,996 77.15 0.0005
2018-08-09 2018-06-30 13F ALDEYRA THERAPEUTICS COM 01438T106 780,744 741,337 1,881.23 6,207 1,996.96 0.0003
2018-05-09 2018-03-31 13F ALDEYRA THERAPEUTICS COM 01438T106 39,407 1,713 4.54 296 15.63 0.0000
2018-02-09 2017-12-31 13F ALDEYRA THERAPEUTICS COM 01438T106 37,694 27 0.07 256 -5.54 0.0000
2017-11-14 2017-09-30 13F ALDEYRA THERAPEUTICS COM 01438T106 37,667 -1,877 -4.75 271 47.28 0.0000
2017-08-10 2017-06-30 13F ALDEYRA THERAPEUTICS COM 01438T106 39,544 4,449 12.68 184 5.14 0.0000
2017-05-12 2017-03-31 13F ALDEYRA THERAPEUTICS COM 01438T106 35,095 35,095 175 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.